Roschier represented Frazier Life Sciences in its investment in Egetis Therapeutics
Egetis Therapeutics AB (publ) has carried out a SEK 172 million equity private placement of new shares led and subscribed for by US healthcare investor Frazier Life Sciences. Roschier represented Frazier Life Sciences in connection with the transaction.
US healthcare investor Frazier Life Sciences has made a SEK 155 million investment in Egetis Therapeutics, an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment. Egetis Therapeutics is listed on the Nasdaq Stockholm main market.
Frazier Life Sciences invests globally in private and publicly-traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences’ funds comprise over $3.3 billion in capital raised, including venture funds focusing on company creation and private companies, and a public fund focused on small and mid-cap public companies.